Valneva Shares Drop 3.57% Breaking Support at €2.21

Valneva Breaks Support at €2.21 and Slides Among the Biggest Losers of the SBF 120

Valneva's stock falls 3.57% to €2.19 mid-morning, after breaking its support level at €2.21 during the session. The stock is among the biggest losers in the SBF 120, which is up by 0.25%. The session extends a deteriorating trajectory: the biotech is down 11.5% over a month and 22.8% over three months. The decline continues a troubling trend, previously noted at the breach of the €2.26 threshold in early June with the break of a previous technical level. The stock is now significantly below its moving averages: 7.6% from the MM20 (€2.37), 10.3% from the MM50 (€2.44), and nearly 40% from the MM200 (€3.64), confirming the degradation of the medium and long-term trend. The RSI at 43 remains in a neutral zone, indicating that the day's drop has not yet shifted into a clear oversold configuration. The annual general meeting, convened this Thursday, June 25, is by nature a statutory appointment with no market effect in itself. It takes place in a deteriorated stock market environment for the biotech, whose capitalization reflects commercial uncertainty around its travel vaccines.

Lowered 2026 Guidance Continues to Weigh on Trajectory

The fundamental context sheds light on the underlying decline. During the first quarter of 2026 announcement on May 13, 2026, the company adjusted its revenue forecasts for the year, now targeting between €135 and €150 million. This adjustment reflected particularly unfavorable trends in the adoption of travel vaccines and a decline in third-party product sales, two risks identified in the quarterly report. The management then highlighted a focus on key strategic projects, including LB6V, the Lyme disease candidate developed in partnership with Pfizer, presented at several investor conferences in June. On the stock market front, the break below the €2.21 support further weakens the graphical configuration. Beyond today's general meeting, the next significant financial update expected by the market is the mid-year publication, which will measure the gap between the commercial trajectory and the revised revenue range.